The classification of AML with the biallelic CEBPA mutation in the European Leukemia Net (ELN) guidelines as AML with favorable risk reflects its improved survival outcomes, highlighting the need for molecular diagnostics to guide therapy [83]. Here, CEBPA is linked to acute myeloid leukemia.